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Abstract: Nanoparticles have been extensively studied for drug delivery and targeting to specific 
organs. The functionalization of the nanoparticle surface by site-specific ligands (antibodies, 
peptides, saccharides) can ensure efficient recognition and binding with relevant biological targets. 
One of the main challenges in the development of these decorated nanocarriers is the accurate 
quantification of the amount of ligands on the nanoparticle surface. In this study, nanostructured 
lipid carriers (NLC) were functionalized with N-acetyl-D-galactosamine (GalNAc) units, known to 
target the asialoglycoprotein receptor (ASGPR). Different molar percentages of GalNAc-
functionalized surfactant (0%, 2%, 5%, and 14%) were used in the formulation. Based on ultra-high-
performance liquid chromatography separation and evaporative light-scattering detection (UPLC-
ELSD), an analytical method was developed to specifically quantify the amount of GalNAc units 
present at the NLC surface. This method allowed the accurate quantification of GalNAc surfactant 
and therefore gave some insights into the structural parameters of these multivalent ligand systems. 
Our data show that the GalNAc decorated NLC possess large numbers of ligands at their surface 
and suitable distances between them for efficient multivalent interaction with the ASGPR, and 
therefore promising liver-targeting efficiency. 
Keywords: Nanostructured Lipid Carriers; N-acetyl-D-galactosamine ligand; Surface 
Functionalization; Ligand Quantification 
 
1. Introduction 
Since the early 1990s, nanomedicine has emerged as one of the most exciting areas of medical 
research. Different types of nanoparticles, including inorganic and organic nanoparticles, present 
unique properties in terms of physical (optic, electronic, and/or magnetic), chemical, and biological 
properties that can be exploited for various medical applications such as therapy, diagnosis, drug 
delivery, and vaccine development [1,2]. To maximize therapeutic efficiency and minimize undesired 
side effects of active pharmaceutical ingredients (API), increasing attention is being paid to lipid 
nanoparticles. These nanocarriers, including lipid nano-emulsions, solid lipid nanoparticles, lipid 
nanocapsules and nanostructured lipid nanocarriers (NLC), can encapsulate active compounds, 
protect them from the degradation by the biological media and then maximize their bioavailability 
[3–6]. Due to their lipid nature, they offer further advantages in terms of biocompatibility, safety of 
used components, production cost and controlled release of the payload [7]. Moreover, the inherent 
properties of these nanocarriers affect the dose limitation of administrated compounds by modifying 
their biodistribution pattern, providing protection against clearance, and/or increasing their 
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availability in targeted organs, tissues, or cells [3,4,8]. In this context, NLC (nanostructured lipid 
carriers) introduced by Muller in 2002 [5], are particularly attractive due to the absence of organic 
solvent for their preparation, their high stability in vivo and their highly efficient encapsulation of 
lipophilic compounds [3,5,9,10]. Recently, a new generation of NLC based on the use of FDA 
approved components has been developed by our team [11]. These nanoparticles hold great promise 
for in vivo imaging and drug delivery [12,13]. Their efficient encapsulation of lipophilic compounds 
as well as their long-life colloidal stability (>1 year for certain formulations) make them ideal 
candidates as drug delivery systems. 
Recent advances in drug delivery suggest the modification of the surface of nanocarriers to affect 
their physicochemical properties and to ensure API supply at the targeted location. The most popular 
coating component extensively used in this context is polyethylene glycol (PEG) [14]. Attachment of 
PEG to the surface may reduce interactions with proteins and uptake in macrophages, resulting in 
increased blood circulation/retention time [14–17]. Such “passive” targeting can ensure the 
accumulation of the drug in disease locations, such as tumors, and then improve its therapeutic 
benefit. 
To go further in specific API delivery at the required site, active targeting nanocarriers have been 
explored [18,19]. Numerous cell-specific receptors are involved in essential biological functions, 
including signaling, trafficking, and transducing, and are recognized by ligands, including proteins, 
peptides, antibodies, nucleic acids, vitamins, and carbohydrates. To actively target diseased tissues 
or organs, ligands known to specifically interact with cell-specific receptors may be attached at the 
surface of nanocarriers. Carbohydrates, including mono-, oligo-, and polysaccharides, possess key 
recognition roles, mainly at the surface of cells, in numerous biological processes [19]. For instance, 
monosaccharides exhibit specific binding/interaction to cell-specific receptors, such as C-type lectin 
receptors, expressed on the surface of various cell types. In particular, the asialoglycoprotein receptor 
(ASGPR), a C-type lectin mainly expressed on the surface of hepatic cells [20,21], recognizes 
specifically galactose (Gal) and N-Acetylgalactosamine (GalNac) with an affinity for GalNAc 
approximately 50-fold higher than for Gal [22–24]. This receptor has been extensively studied as a 
promising candidate for liver-targeted drug delivery [19,25]. To further improve the affinity of Gal 
or GalNAc monosaccharide toward this hepatic receptor, multivalent interactions, such as those 
offered by the surface of decorated nanocarriers, have proven to be a promising strategy to improve 
efficiency as well as selectivity of the recognition process [26–33]. In this multivalent approach, 
several structural parameters, such as the nature, number and spatial organization of the 
monosaccharide, play key roles in the recognition process through the ASGPR. In molecular systems, 
optimized recognition was achieved when monosaccharides were approximately 20 Å apart [30]. 
Furthermore, several Gal decorated lipid nanoparticles have shown higher uptake in hepatic cells 
than their non-functionalized counterparts [34–37]. 
One of the main challenges in the development of these targeted nanocarriers is the access to 
well-defined multivalent carbohydrate systems, which requires the precise quantification of the 
number of monosaccharide ligands actually present at the surface of the nanoparticles. This latter 
parameter is indeed very important to get a better understanding of the recognition processes 
between the functionalized nanocarriers and targeted receptors. In the few studies reporting Gal or 
GalNAc functionalized lipid nanoparticles [35,38], the authors assume the total incorporation of the 
saccharide moieties on the nanoparticle surface, and to our knowledge, the precise quantification of 
saccharide ligands at the surface of nanocarriers has never been performed. 
In this work, nanostructured lipid carriers (NLC) were decorated with GalNAc monosaccharide 
units to target the ASGPR mainly expressed at the surface of liver cells. The NLC prepared using the 
ultrasonication technique were formulated using different initial amounts of GalNAc modified 
amphiphilic PEG-derived surfactants. To assess the exact amount of GalNAc incorporated and 
present at the NLC surface, a method leading to the quantification of PEG-modified molecules was 
developed based on ultra-high-performance liquid chromatography as a separative method and 
evaporative light-scattering detection for detection (UPLC-ELSD).  
2. Results 
Int. J. Mol. Sci. 2019, 20, 5669 3 of 16 
 
2.1. SA-PEG100-GalNAc 6 Synthesis 
A novel N-acetyl-D-Galactosamine stearic acid (SA) PEG derivative (SA-PEG100-GalNAc 6) was 
synthesized according to synthetic Scheme 1. This derivative presents bifunctional properties with a 
lipophilic anchor moiety (SA) for stable incorporation into the nanostructured lipid carriers and an 
N-acetyl-D-Galactosamine moiety for recognition by GalNAc specific receptors/transporters (e.g., 
asialoglycoproteins). The PEGylated chain of 6 comprised of about 100 ethylene oxide units, longer 
than that of MyrjTMS40 surfactant (about 40 ethylene oxide units) coating and stabilizing the NLC 
surface. 
SA-PEG100-GalNAc 6 was obtained by grafting the synthetic GalNAc-SSPy derivative 5 and SA-
PEG-maleimide 4 via a maleimide/thiol link (Scheme 1). The GalNAc-SSPy derivative 5 was 
synthesized according to a previously described procedure in four steps with an overall yield of 10% 
[33]. The stearate chain was grafted onto commercial NH2-PEG100-NHBoc using an amide bond using 
BOP as a coupling agent to give after deprotection the SA-PEG100-NH3+TFA- 3 with an overall yield 
of 52% (Scheme 1). Then the maleimide group was grafted using BOP coupling. After the reduction 
of the disulfide bond present in the GalNAc-SSPy derivative 5 with TCEP, the free-thiol group reacted 
specifically with the maleimide function present on the SA-PEG100-maleimide 4 derivative to lead to 
the desired SA-PEG100-GalNAc compound 6 with an 87% yield. The reaction was followed by 1H 
NMR spectroscopy and stopped after the complete disappearance of the maleimide protons (6.7 ppm) 
(Supplementary Information, Figure S1). 
 
Scheme 1. Synthesis of SA-PEG100-GalNAc 6 - Reactants and conditions : (a) Stearic acid, BOP, DIEA, 
DCM, 61%, (b) TFA, DCM, 85%, (c) 6-maleimidohexanoic acid, BOP, DIEA, DCM, 94%, (d) TCEP, 
ACN/H2O, 87%. 
2.2. Formulation of Nanostructured Lipid Carriers 
NLC with and without different molar percentages of SA-PEG100-GalNAc 6 were formulated by 
ultrasonication according to previously described protocols [11]. Four different formulations were 
prepared with respectively 0% (Formulation A), 2.0% (Formulation B), 5.3% (Formulation C) and 
13.6% (Formulation D) of SA-PEG100-GalNAc compared to MyrjTM S40 (molar percentages). The ratios 
of MyrjTM S40 and SA-PEG100-GalNAc varied while the total mass of PEGylated compounds, as well 
as the mass of other ingredients, were kept constant. Formulation E comprising 13.6% of MyrjTM S100 
(S100, long-chain PEG surfactant of around 100 ethylene oxide units) was also synthesized as a 
control. Component quantities are reported in Table 1. 
Table 1. Composition of formulations A, B, C, and D (quantities in mg). 
 Ingredients A B C D E 
 Soybean oil 85 85 85 85 85 
Lipid phase Suppocire™NB 245 245 245 245 245 
 Lipoid™ s75 65 65 65 65 65 
Aqueous phase 
Myrj™S40 345 327 298.3 241.1 241.1 
SA-PEG100-GalNAc 0 18.7 46.7 105.4 - 
SA-PEG100-GalNAc (% mol) 0 2.1 5.3 13.6 - 
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Myrj™S100 - - - - 105.4 
PBS qsp 2 mL qsp 2 mL qsp 2 mL qsp 2 mL qsp 2 mL 
Dynamic light scattering (DLS) was used to determine the NLC hydrodynamic diameter, 
polydispersity index (PDI), and zeta potential, as summarized in Table 2. Formulations A and B 
displayed similar hydrodynamic diameter and PDI, which were consistent with previously described 
studies [11]. Formulations C and D showed larger hydrodynamic diameter, and larger PDI for 
Formulation D. These differences may be due to the higher amount of SA-PEG100-GalNAc, which 
polymer chain presents a 2.5 fold larger number of ethylene oxide units than MyrjTMS40 [11]. This 
hypothesis was confirmed by data of Formulation E, comprising the same ratio of MyrjTMS100 long-
chain surfactant. Zeta potential values were not significantly different: All nanoparticles presented 
surface charge close to neutrality, with a slightly negative value (presence of small quantities of 
hydrolyzed fatty acids in wax and oil components). 
Table 2. DLS characterization of formulations A, B, C, and D. 
 A B C D E 
Hydrodynamic diameter (nm) 41.8 ± 1.3 37.2 ± 1.3 52.4 ± 1.4 59.8 ± 0.6 63.9 ± 1.5 
PDI 0.11 ± 0.02 0.11 ± 0.03 0.11 ± 0.02 0.14 ± 0.02 0.18 ± 0.02 
Zeta potential (mV) −3.9 ± 1.3 −5.9 ± 2.1 −6.2 ± 2.5 −6.3 ± 2.4 −4.4 ± 2.5 
Colloidal stability during storage at 4 °C 1 year 5 months 3 months 3 weeks 1 month 
The long-term colloidal stability of formulations A–E was evaluated by the measurement of 
hydrodynamic diameter and PDI over storage time. As described previously [11], NLC issued from 
Formulation A were stable over one year (diameter increase < 10%, PDI < 0.2), whereas formulation 
stability decreased with increased content of SA-PEG100-GalNAc or Myrj™S100 (Table 2). Longer 
PEG100 chain could present different conformation than PEG40, modifying the surfactant organization 
in the nanoparticle shell that could account for the reduced oil/water stability leading to NLC 
destabilization. However, formulations B–E were stable enough to perform reliable further 
characterization experiments.  
2.3. Development of the Analytical Method for the Quantification of GalNAc Units Grafted on NLC Surface 
2.3.1. Optimization of the Analytical Conditions 
To analyze each component of the formulations, NLC were disassembled by precipitating the 
lipids in acetonitrile. Therefore, components of NLC were first separately analyzed by UPLC-ELSD 
according to previously described analytical methods [39]. Briefly, two UPLC-ELSD methods were 
previously developed for the analytical qualification of NLC, one using a reverse-phase (RP) C18 
column (method A), separating and quantifying MyrjTM S40 and lipids, and the second one, a HILIC 
column (method B) for the assessment of lecithin components. Analytical method A, which 
comprised a two-step gradient elution program, succeeded in analyzing the exact content of 
Myrj™S40 (three compounds), soybean oil (15 compounds), and Suppocire™NB (15 compounds) 
[39]. To specifically analyze additional SA-PEG100-GalNAc, the proposed RP-UPLC-ELSD method 
was herein optimized by extending the first gradient step (from 3 to 15 min), thus allowing better 
separation of Myrj™S40 and SA-PEG100-GalNAc. The gradient elution program used in this study is 
reported in Table 3 (Materials and Methods). The chromatogram of all the NLC separated 
components are superimposed in Figure 1. 
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Figure 1. Combination of free nanostructured lipid carriers (NLC) component chromatograms (1 
mg/mL for each compound). 
According to the supplier information, MyrjTM S40 is a non-ionic surface active agent which was 
calculated to contain 71.3% (w/w) of three different compounds: PEG-C18 with 18 carbon lipophilic 
chain (PEG-stearate), PEG-C16 with 16 carbon lipophilic chain (PEG-palmitate) and PEG-OH without 
lipophilic chain [39]. They appeared in the chromatogram (Figure 1) as three peaks at 1.9, 6.4, and 7.2 
min respectively. SA-PEG100-GalNAc appeared in the chromatogram as a single peak at 5.8 min. 
SuppocireTM NB is composed of a mixture of di- and triglycerides of various acyl chain lengths (C8–
C18). It appeared in the chromatogram as 15 peak clusters in the range of 8 to 26 min, and elution 
occurred according to the equivalent carbon number. Super refined soybean oilTM was identified as 
being a mixture of C16–C18 unsaturated triglycerides, and appeared in the chromatogram as eight 
peak clusters in the range of 17 to 24 min [39]. Lipoid TM s75 is a phospholipid and is then mainly 
composed of phosphatidylcholine with a slight proportion of phosphatidylethanolamine and 
lysophosphatidylcholine. It appeared as a peak cluster between 8 min and 12 min. Lipoid TM s75 
chromatogram was then overlapping SuppocireTM NB peaks but it did not affect the quantification 
process of MyrjTM S40 and SA-PEG100-GalNAc 6, as lipids, including Lipoid TM s75, were removed 
during NLC sample preparation before UPLC-ELSD analysis (see below).  
Interestingly, MyrjTM S40 and SA-PEG100-GalNAc 6 appeared in a different non-overlapping area 
of the chromatogram (respectively 1.9, 6.4, and 7.2 min for MyrjTM S40 compounds, and 5.8 min for 
SA-PEG100-GalNAc 6), and therefore, respective quantification was possible. To examine hypothetic 
interferences between components of disassembled NLC that would modify retention times, a 
mixture with 96/4 molar ratio of MyrjTM S40 and SA-PEG100-GalNAc was analyzed by UPLC-ELSD 
(Supplementary Information, Figure S2). No interference among peaks was observed in the 
chromatogram. These results demonstrated the negligible influence of the matrix on the SA-PEG100-
GalNAc 6 and MyrjTM S40 quantification process.  
2.3.2. Calibration Curves for MyrjTM S40 and SA-PEG100-GalNAc 6 
To quantify the amount of SA-PEG100-GalNAc 6 and the components of Myrj™S40 (PEG40-OH, 
PEG40-C16, and PEG40-C18) at the NLC surface, calibration curves were established for these 
compounds by triplicating at seven concentrations from 15.6 µg/mL to 1 mg/mL obtained by half 
cascade dilution from stock solutions. Calibration curves for SA-PEG100-GalNAc 6, Myrj™S40, and 
each its components (PEG40-OH, PEG40-C16, and PEG40-C18) are reported respectively in Figure 2 (SA-
PEG100-GalNAc 6), and Figures S3 and S4 (Supplementary Information, Myrj™S40 components). The 
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peak areas of SA-PEG100-GalNAc 6, PEG40-OH, PEG40-C16 and PEG40-C18 were plotted against 
surfactant concentration. As previously used, a second-order polynomial (quadratic) was used as a 
fitting model [39], producing an excellent correlation coefficient (R2 values comprised between 0.9999 
and 0.9994) (Figures 2, S3, and S4).  
 
Figure 2. Calibration curve of free SA-PEG100-GalNAc 6. 
Equation of the calibration curves for SA-PEG100-GalNAc 6 and MyrjTM S40 components were 
established (Figures 2, S3, and S4). Additionally, limits of detection (LOD) were measured as 0.8 and 
3.5 µg/mL, respectively for PEG-OH and SA-PEG100-GalNac 6, and limits of quantification (LOQ) 
were 2.4 and 10.7 µg/mL respectively. Analyses were repeatable (relative standard deviation (RSD) 
of 1.4% and 1.5%, respectively for PEG-OH and SA-PEG100-GalNAc 6). The values obtained for PEG-
OH were in agreement with a previous study [39]. Once established and validated, the analytical 
method was used to quantify the exact percentage of SA-PEG100-GalNAc 6 and components of MyrjTM 
S40 that were incorporated into NLC. 
2.3.3. Sample Preparation 
To analyze nanoparticle components, NLC were first disassembled by precipitation with 
acetonitrile. Supernatants containing SA-PEG100-GalNAc 6 and MyrjTM S40 were analyzed by UPLC-
ELSD after appropriate dilution (Figure 3). The pellets containing lipids (Lipoid TM s75, SuppocireTM 
NB and Soybean oilTM) were analyzed to make sure that no SA-PEG100-GalNAc 6 or MyrjTM S40 was 
precipitated in the pellet. Free SA-PEG100-GalNAc 6 and MyrjTM S40 underwent the same treatment 
to assess the stability of these compounds during precipitation and no degradation was observed. 
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Figure 3. Sample preparation for the UPLC-ELSD analysis of SA-PEG100-GalNAc 6 and Myrj™S40 
components in disassembled NLC (PEG Gal-NAc peak underlined in red in the chromatogram). 
2.3.4. Quantification Results 
Chromatograms of disassembled NLC are reported in Supplementary Information Figure S5. 
The integration of peak areas corresponding to SA-PEG100-GalNAc 6 and MyrjTM S40 components 
enabled the quantification of SA-PEG100-GalNAc 6 on the surface of the different formulations. For 
all analyzed formulations, obtained concentrations were above the LOQ, both for PEG-OH and SA-
PEG100-GalNac 6. The analyses of all formulations A–D were repeatable (RSD < 2%). Calculations are 
reported in Supplementary Information, Tables S1–S3. 
Incorporation yields and experimental molar % of SA-PEG100-GalNac 6 in the different 
formulations are plotted in Figure 4. Incorporation yields in formulations B, C, and D, showed similar 
results with about 80%–90% for SA-PEG100-GalNAc 6, lower values from 32% to 41% were obtained 
for MyrjTM S40 (Figure 4, Table S1). Formulations B, C, and D were initially formulated with 2.0%, 
5.3% and 13.6 molar % of SA-PEG100-GalNAc 6 respectively. Because of the larger incorporation yield 
of SA-PEG100-GalNAc 6 compared to MyrjTM S40, Formulation B finally exhibited 4.6% of SA-PEG100-
GalNAc, Formulation C 13.9%, and Formulation D 23.3% (Supplementary Information, Table S1). In 
formulated nanoparticles, these values corresponded to 135 SA-PEG100-GalNAc 6 at NLC surface of 
Formulation B (1 GalNAc every 32 nm²), 333 SA-PEG100-GalNAc 6 for Formulation C (1 GalNAc every 
26 nm²) and 650 SA-PEG100-GalNAc 6 for Formulation D (1 GalNAc every 17 nm²) (Supplementary 
Information, Tables S2 and S3, Figure 5). 
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Figure 4. Quantification results on disassembled NLC (error bars: standard deviation of three 
different experiments). 
 
Figure 5. Surface density of SA-PEG100-GalNAc 6 per particle. 
3. Discussion 
Nanostructured lipid carriers were designed, made of a lipid core composed of a mixture of 
liquid (soybean oil) and solid (Suppocire™ NB) lipids, stabilized by a layer of surfactants which 
contained GalNAc-modified ligands to actively target liver hepatocytes over-expressing ASGPR. 
Except for SA-PEG100-GalNAc 6 synthesized specifically for the study and whose toxicity is unknown, 
the commercial components used for NLC formulation are non-toxic, biocompatible, and FDA (Food 
and Drug Administration) or EMA (European Medicines Agency) approved. NLC present numerous 
advantages such as biocompatibility and in vivo tolerance [7,12], controlled drug release by tuning 
solid/liquid lipid ratio [40], and the possibility to be produced at middle to large scales by high-
pressure homogenization [41].  
Surface functionalization of lipid-based nanocarriers can be achieved by various non-covalent 
or covalent surface engineering techniques [18]. One is the covalent attachment of targeting ligands 
following the synthesis of nanocarriers presenting functional chemical groups on their surface. This 
covalent ligation is usually based on classical “click reactions” that can be performed in water where 
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the nanocarriers are suspended. Additionally, such mild conditions are also favorable as they do not 
damage the structure of fragile targeting moieties, such as proteins. Classical reactions include amide 
bond formation, thiol-maleimide Michael addition, disulfide bond formation, hydrazine and oxime 
ligation, azide-alkyne 1,3 dipolar cycloaddition [42,43]. For example, amino-functionalized 
preformed solid lipid nanoparticles have been previously decorated by Gal moieties taking benefit 
of the D-galactose open-chain form comprising aldehyde group, involving the formation of a Schiff’s 
base, further reduced to a secondary amine [34].  
The “post-synthesis functionalization” strategy is the preferred route for the attachment of 
targeting ligands on inorganic nanocarriers or some polymer nanoparticles. However, the “pre-
functionalization” strategy is generally preferred for liposomes or solid lipid nanoparticles, unless 
the targeting moiety to attach is a very precious biological material, introduced in very low quantity 
at the nanocarrier surface, or can be degraded during the nanoparticle assembly process. Indeed, in 
the latter strategy, the characterization of ligand-modified surfactants can be carefully performed by 
usual techniques such as NMR, and the quantity of targeting ligands introduced during the 
formulation well controlled. Using this strategy, SiRNA/lipid nanoparticles decorated by PEGylated-
GalNAc surfactants were designed to deliver genes in hepatocytes [44,45]. Gal targeting moieties 
were also introduced at the surface of different liposomes or lipid nanoparticles using Gal derivatives 
of cholesterol [38], alpha-tocopherol [46], or DSPE (distearoyl phosphatidylethanolamine) [35,36,47]. 
However, the number of Gal or GalNAc moieties introduced at the surface of the nanoparticles was 
not experimentally quantified, and when calculated, total incorporation of surfactants in the 
formulation was assumed [35].  
In the present study, the “pre-functionalization strategy” was used. GalNAc-functionalized 
PEGylated surfactants were designed, synthesized, and characterized, before being introduced 
during the formulation of nanostructured lipid carriers in different proportions. GalNAc was used 
as a decorating ligand since it displays about 50-fold higher affinity for ASGPR than Gal [22–24]. 
Attachment of the GalNAc moiety to the PEG chain was performed in acetonitrile/water mixture by 
the classic thiol-maleimide coupling. Experiments using dibenzocyclooctyne (DBCO) terminated 
surfactant for copper-free click ligation were performed as well but stopped rapidly due to the poor 
stability of the DBCO derivative in aqueous media. The PEG-GalNAc surfactants were designed with 
longer PEG chains (about 100 ethylene oxide units) than this stabilizing nanoparticle surface 
(Myrj™S40, around 40 ethylene oxide units), to promote efficient interactions of GalNAc moieties 
with ASGPR expressed on the cell surface. However, when increasing the percentage of long PEG 
surfactants, nanoparticle diameter increased whereas their colloidal stability decreased (Table 2), as 
previously observed [11]. This could be accounted for by a change of oil/water interface tension 
and/or PEG conformation (from coil to brush for longer chains). An optimal functionalization ratio 
was therefore defined at 10% molar of SA-PEG100-GalNAc 6 introduced during formulation. 
To get a precise characterization of the nanoparticles and measure the quantity of GalNAc 
moieties actually introduced on the NLC surface, namely the ligand density, a UPLC-ELSD 
quantitative method was developed. It allowed to demonstrate that SA-PEG100-GalNAc 6 was 
incorporated at 80%–90% in formulations B, C, and D. Myrj™S40 had a lower incorporation yield 
from 32% to 41% in formulations A, B, C, and D. This lower percentage can be partly explained by 
the composition of the commercial Myrj™ S40 product. As recently reported [39], this component is 
composed of three different compounds: PEG40-OH, PEG40-C16, and PEG40-C18 in approximately equal 
quantities (30.1% w/w, 34.6% w/w, and 35.3% w/w, respectively). Thanks to their aliphatic C16 or C18 
chain that interacts with Lipoid TM s75 phospholipid chain and triglycerides, PEG-C16 and PEG-C18 
are quite well anchored at the lipid core/water interface of the nanodroplets, similarly to SA-PEG100-
GalNAc 6. On the other hand, PEG-OH, because of its lack of lipophilic anchor, is eliminated during 
purification of the formulation by dialysis [39]. Therefore, at the end of the purification step, SA-
PEG100-GalNAc 6/Myrj™ S40 molar ratio was increased in comparison to ratios initially introduced 
for the formulation step (4.6% versus 2.1% for Formulation B, 13.9% versus 5.3% for Formulation C, 
and 23.3% versus 13.6% for Formulation D). From the above quantification data of the surfactants 
and particle diameter determined by DLS, the number of GalNAc moieties introduced and their 
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density on the NLC surface can be calculated (Supplementary Information, Tables S2 and S3). The 
particle hydrodynamic diameter increased significantly when the number of GalNAC units increased 
per particle (from 40 to 60 nm), and this effect was taken into account for the GalNAc surface density 
calculation. Formulations of nanoparticles exhibited then 1 GalNAc every 32 nm² (Formulation B), 1 
GalNAc every 26 nm² (Formulation C), and 1 GalNAc every 17 nm² (Formulation D). The mean 
distance between GalNAc units could be estimated to be 5.6 nm (Formulation B), 5.2 nm (Formulation 
C), and 4.1 nm (Formulation D). 
Multivalent interactions with the ASGPR, and therefore the targeting efficiency, are highly 
dependent on the number and the spatial arrangement of the monosaccharide ligands [26–33]. The 
“optimal distance” between Gal units to benefit from multivalent interactions with the receptor was 
estimated by Lee et al. to be 15–20 Å apart in a triangle geometry [30,31].  
Several GalNAc- or Gal-functionalized lipid nanoparticles described in the literature have 
already demonstrated their interest in delivering therapeutic compounds to the liver, and their 
ASGPR recognition efficiency was assumed to be correlated with the surface density of Gal or 
GalNAc residues [29]. However, no quantification protocol was developed, and only in a few cases, 
the number of Gal or GalNAc residues were roughly estimated based on the hypothesis of full 
incorporation of saccharide-surfactants at the nanoparticle surface [35,36,38,44–47]. Among these 
studies, the Gal ligand density decorating the surface of lipid nanocapsules investigated by Morille 
et al. for gene therapy can be calculated from reported data, assuming total incorporation of the 
saccharide moieties (Supplementary Information, Table S4, Figure S6) [35]. Interestingly, these data 
described nanoparticles with lower density (at best 1 Gal ligand/57 nm2) than herein quantified at the 
NLC surface (at least 1 GalNAc ligand/32 nm2). Our system, therefore, improves the GalNAc-GalNAc 
distance (about 4 nm), and is closer to the “optimal distance” estimated by Lee et al. (15–20 Å) [30,31] 
to benefit from multivalent interactions. Morille et al. also reported that DSPE-PEG2000-Gal coating at 
1 ligand/57 nm2 did not induce significant effect in improving lipid nanocapsule transfection 
efficiency in primary rat hepatocytes, whereas F108-Gal coated nanocapsules (1 ligand/107 nm2) 
strongly improved gene delivery These results, not correlated to the Gal ligand surface density, 
suggested a difference in sugar accessibility. They illustrate the importance of the spatial arrangement 
of the terminal Gal units and highlight the complexity of these systems and their comparison. For 
herein described NLC, the use of a surfactant-containing about 100 ethylene oxide units should make 
the GalNac ligands more accessible to the receptor. In addition, in comparison to previously 
described nanoparticles [35,36,38,44–47], their smaller size, their higher surface density and the use 
of GalNac having a 50 times higher affinity than Gal, should lead to improved multivalent interaction 
with the ASGPR. Future studies will be directed to evaluate the ability of these GalNAc-decorated 
NLC to efficiently enter hepatic cells.  
4. Materials and Methods  
4.1. General Information 
Chemical reactants and solvents were purchased from Sigma-Aldrich (Saint Quentin Fallavier, 
France) and were used without further purification unless specified. Compound 5 was obtained 
according to previously reported procedures [33]. BocNH-PEG100-NH2 was purchased from Iris 
Biotech GmbH (Marktredwitz, Germany). SuppocireTM NB and Labrafac were purchased from 
Gattefossé (Saint-Priest, France). MyrjTM S40 and MyrjTM S100 (poly(ethylene glycol) surfactants with 
respectively about 40 and 100 ethylene oxide units), and super-refined soybean oil were supplied by 
CRODA (Chocques, France). LipoidTM s75 was purchased from Lipoid GmbH (Ludwigshafen, 
Germany). SpectraPorTM dialysis membrane of 12–14,000 MWCO was purchased from Roth Sochiel 
EURL (Lauterbourg, France). HPLC grade solvents were obtained from VWR Scientific (Fontenay-
sous-Bois, France). 
All water solutions were prepared from ultra-pure laboratory-grade water that has been filtered 
and purified by reverse osmosis using Millipore Milli-QTM cartridge system (resistivity 18.2 MΩ.cm 
at 25 °C, Merck, Fontenay-sous-bois, France). Thin-layer chromatography (TLC) was performed on 
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silica gel 60 F254 (Merck). 1H NMR spectra were recorded on a Bruker Avance 400 spectrometer 
(Bruker, Wissembourg, France). Chemical shifts (δ) are reported in ppm with the solvent as the 
internal reference.  
4.2. Synthesis  
4.2.1. SA-PEG100-NHBoc 2 
To a solution of stearic acid (1.03 g, 3.60 mmol) in CH2Cl2 (80 mL), benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP, 1.60 g, 3.60 mmol) was added. 
After complete dissolution, commercially available BocNH-PEG100-NH2 1 (5.0 g, 1.03 mmol) and N,N-
diisopropylethylamine (DIEA; 470 mg, 3.60 mmol) were added. After stirring for 2 h at room 
temperature, the resulting mixture was concentrated under reduced pressure. Precipitation was 
obtained upon the addition of cold diethyl ether. The precipitate was filtered, dissolved in water and 
purified by dialysis for 48 h versus a large volume of water (MW cut-off 1 kDa). After lyophilization, 
SA-PEG100-NHBoc 2 was obtained as a white powder (3.15 g, 0.63 mmol, 61% yield).  
1H NMR (300 MHz; CDCl3)—δ: 0.87 (t, J = 7.2 Hz; 3H), 1.13–1.36 (m, 28H), 1.44 (s, 9H), 1.60 (quint, 
J = 15.1, 7.6 Hz, 2H), 2.42 (t, J = 7.5 Hz, 2H), 3.30 (t, J = 5.0 Hz, 2H), 3.40 (t, J = 5.0 Hz, 2H), 3.48–3.80 (m, 
360H), 3.87 (t, J = 5.0 Hz, 2H), 7.79 (bs, 1H). 
4.2.2. SA-PEG100-NH3+TFA− 3 
To a solution of SA-PEG100-NHBoc 2 (1.61 g, 0.30 mmol) in CH2Cl2 (10 mL), trifluoroacetic acid 
(TFA, 6.32 g, 55 mmol) was added. After stirring for 1 h at room temperature, the resulting mixture 
was concentrated under reduced pressure, and precipitation was obtained upon addition of cold 
diethyl ether. The precipitate was filtered, dissolved in water, and purified by dialysis for 48 h versus 
a large volume of water (MW cut-off 1 kDa). After lyophilization, SA-PEG100-NH3+TFA- 3 was 
obtained as a white powder (1.37 g, 0.26 mmol, 85% yield).  
1H NMR (400 MHz ; CDCl3)—δ: 0.87 (t, J = 7.2 Hz, 3H), 1.13–1.36 (m, 28H), 1.60 (quint, J = 15.1, 
7.6 Hz, 2H), 2.15 (t, J = 7.5 Hz, 2H), 3.17 (bt, 2H), 3.4 (m, 4H), 3.48–3.80 (m, 360H), 3.87 (t, J = 5.0 Hz, 
2H), 6.14 (bs, 1H), 7.90 (bs, 2H). 
4.2.3. SA-PEG100-Maleimide 4 
To a solution of 6-maleimidohexanoic acid (8.40 mg, 0.040 mmol) in CH2Cl2 (5 mL), BOP (17.5 
mg, 0.04 mmol) was added After stirring for 10 min under argon atmosphere, SA-PEG100-NH3+TFA- 
3 (100 mg, 0.020 mmol) and DIEA (5 µL, 0.040 mmol) were added. The reaction mixture was stirred 
for 1 h until disappearance of starting SA-PEG100-NH3+TFA- 3 (TLC SiO2, eluent CH2Cl2/CH3OH 9/1 
v/v, ninhydrine). The resulting mixture was concentrated under reduced pressure and precipitation 
was obtained upon the addition of cold diethyl ether. SA-PEG100-maleimide 4 was obtained as a white 
powder (97.6 mg, 0.02 mmol, 94% yield). 
1H NMR (400 MHz, CDCl3)—δ: 0.87 (t, J = 6.7 Hz, 3H), 1.13–1.36 (m, 28H), 1.62 (qd, J = 15.1, 7.6 
Hz, 6H), 1.80 (t, J = 6.4 Hz, 2H), 2.15 (t, J = 7.6 Hz, 4H), 3.04–3.21 (m, 4H), 3.40–3.48 (m, 5H), 3.50–3.75 
(m, 360H), 3.81 (t, J = 5.6 Hz 3H), 6.14 (s, 1H), 6.68 (s, 2H). 
4.2.4. SA-PEG100-GalNAc 6 
To a solution of SA-PEG100-maleimide 4 (97.6 mg, 0.019 mmol) and TCEP (23.5 mg, 0.094 mmol) 
in CH3CN (3 mL), a solution of GalNAc-SSPy derivative 5 (18 mg, 0.038 mmol) in H2O (1 mL) was 
added dropwise under argon atmosphere. The resulting yellow solution was stirred at room 
temperature for 5 h. The mixture was concentrated under reduced pressure, and precipitation was 
obtained upon the addition of cold diethyl ether. The precipitate was filtered, dissolved in water, and 
purified by dialysis for 48 h versus a large volume of water (MW cut-off 1 kDa). SA-PEG100-GalNAc 
6 was obtained as a white powder (87.2 mg, 0.016 mmol, 87% yield).  
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1H NMR (400 MHz, D2O) δ : 0.82 (t, J = 6.4 Hz, 3H), 1.21 (s, 28H), 1.42–1.61 (m, 5H), 2.08–2.20 (m, 
3H), 2.38 (dd, J = 17.4, 9.3 Hz, 1H), 2.43–2.55 (m, 4H), 2.56–2.68 (m, 4H), 3.12 (d, J = 12.7 Hz, 1H), 3.19 
(d, J = 6.7 Hz, 1H), 3.30 (t, J = 5.4 Hz, 3H), 3.41–3.47 (m, 3H), 3.50 (t, J = 5.5 Hz, 2H), 3.52–3.56 (m, 2H), 
3.62 (s, 360H), 3.80 (dd, J = 5.4, 3.5 Hz, 3H), 4.42 (d, J = 4.5 Hz, 1H). 
4.3. Formulation of Nanostructured Lipid Carriers 
The lipid phase was prepared by mixing solid (Suppocire™ NB) and liquid (super-refined 
soybean oil) glycerides as well as the lipophilic surfactant Lipoid™ s75, while the aqueous phase was 
composed of the hydrophilic surfactant, MyrjTM S40, eventually SA-PEG100-GalNAc 6 or MyrjTM S100 
and 1X PBS aqueous buffer (100 mM phosphate, NaCl 154 mM, pH 7.4). After homogenization at 45 
°C, both lipid and aqueous phases were crudely mixed and sonication cycles were performed at 45 
°C during 5 min. A conical tip sonicator instrument (AV505 ultrasonic processor, Sonics, Newton, 
Connecticut) with a 3 mm diameter probe was used. Non encapsulated components were separated 
from LNP by dialysis (1× PBS, MW cut-off: 12,000–14,000 Da, overnight). Prior to characterization, 
LNP dispersions were diluted to obtain 5 mL and were then filtered through a 0.22 µm cellulose 
Millipore membrane. Particle concentration was assessed by weighting freeze-dried samples of NLC 
obtained from a known volume. 
4.4. Dynamic Light Scattering  
The hydrodynamic diameter and zeta potential of NLC were measured at 22 °C with a Malvern 
Zeta Sizer Nano instrument (NanoZS, Malvern, Orsay, France) in 0.1× PBS buffer. Physical stability 
was investigated by DLS measurements over one year with samples stored at 4 °C. At least three 
different NLC batches (2 mL, lipid dispersed phase weight fraction: 10%) were used per condition. 
Mean average diameters and polydispersity indices reported were obtained from scattered light 
intensity results. Data were expressed in terms of mean and standard deviation of all the samples for 
each condition, each sample result being the mean of three independent measurements performed at 
25 °C. 
4.5. UPLC-ELSD Analysis 
4.5.1. Sample Preparation 
Each of the standards (MyrjTM S40, SA-PEG100-GalNAc 6, Suppocire™ NB, super-refined soybean 
oil and Lipoid s75™) was weighed on a calibrated, analytical balance and dissolved in a mixture of 
CHCl3/MeOH 2/1 (v/v) to give 1 mg/mL stock solutions. For UPLC-ELSD analysis, nanoparticles were 
disassembled. Three hundred µL of nanostructured lipid carriers were added to 1700 µL of 
acetonitrile. Samples were centrifuged to pellet the lipids after precipitation. Five hundred µL of 
supernatant was added to 1500 µL acetonitrile, and the samples were centrifuged once more to 
remove any remaining lipid in the supernatant. Two hundred fifty µL of supernatant was 
concentrated under reduced pressure and dissolved in 500 µL of a mixture of CHCl3/MeOH 2/1 (v/v) 
to yield solutions with approximatively 1 mg/mL concentration of total PEGylated surfactants 
(MyrjTM S40 and 6) before UPLC-ELSD analysis. 
4.5.2. Chromatographic conditions 
The chromatographic analysis of the NLC ingredients was performed using an Acquity® UPLC 
HClass system (Waters, Guyancourt, France) coupled with an Alltech 3300 evaporating light 
scattering detector (ELSD, Grace, Buchi, Rungis, France). Separation of the different components was 
achieved using a CORTECS UPLC-C18 column (1.6 µm, 150 × 2.1 mm, 90 Å, Waters). Eluents were 
solvent A: Deionized water, B: Methanol, and C: Mixture of isopropanol/acetonitrile 75/25 (v/v). 
Gradients are displayed in Table 3. The drift tube was set at 45 °C with a flow of N2 set at 2.0 L/min 
and a gain at 4. The injected volume was 5 µL and the column temperature was set at 40 °C.  
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Table 3. UPLC gradient elution program for the analysis of NLC ingredients. 
Time (min) Flow (mL/min) A B C 
0 0.25 30 70 0 
3 0.3 10 90 0 
15 0.3 0 100 0 
22 0.3 0 35 65 
25 0.3 0 35 65 
25.1 0.25 30 70 0 
30 0.25 30 70 0 
4.5.3. Calibration Curves 
Stock solutions of SA-PEG100-GalNAc 6 and MyrjTM S40 (1000 µg/mL in CHCl3/MeOH 2/1 (v/v)) 
were diluted in a CHCl3/MeOH mixture (2/1 v/v) to prepare standards. The calibration curves were 
prepared on the same day over the range of 15.625–1000 µg/mL. For validation, each concentration 
point was run in triplicate. Average peak area versus sample concentration curves was plotted to 
establish calibration curves. 
4.5.4. Validation of Analytical Method 
The limit of detection was determined as previously described [39]. Since the whole range 
calibration curves were well fitted using only quadratic equations, only lower concentration 
calibration points (i.e., concentration range of 4–38 µg/mL and 15–63 µg/mL, respectively for PEG-
OH and SA-PEG100-GalNac 6) were used, for which linear calibration curves could be obtained with 
R2 > 0.99. The limits of detection (LOD) and quantification (LOQ) were thus estimated based on the 
standard deviations of the y-intercepts of regressions analysis (σ) and the slope (S), by the following 
equations LOD = 3.3 σ/S and LOQ = 10 σ/S. The repeatability (RSD) of the method was evaluated by 
three independent measurements of standard solutions (at 20 µg/mL and 62.5 µg/mL for PEG-OH 
and SA-PEG100-GalNac 6, respectively) and NLC samples. Precision was expressed as the relative 
standard deviation (RSD, %) of the three independent measurements. 
5. Conclusions 
To our knowledge, it is the first time a full analytical method based on UPLC-ELSD was 
successfully used to quantify the precise amount of GalNAc units present on the surface of lipid 
nanoparticles. The obtained GalNAc-modified NLC of 50 nm diameter presented a quantifiable 
density of ligands comprising between 135 and 650 GalNAc per particle. Compared to reported 
studies, these data would suggest that these nanocarriers are promising vectors to target the ASGPR 
(asialoglycoprotein receptors) mainly expressed at the surface of hepatocytes. Further explorations 
of these nanocarriers, namely their ability to encapsulate and deliver drugs to treat liver-related 
pathologies, such as hepatocellular carcinoma, hemochromatosis, or Wilson’s disease, are currently 
under progress. 
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